Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Baxter
Mallinckrodt
Merck
Harvard Business School

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR ONIVYDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Onivyde

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02231723 ↗ A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer Completed Boston Biomedical, Inc Phase 1 2014-08-01 This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
NCT02231723 ↗ A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer Completed Sumitomo Dainippon Pharma Oncology, Inc Phase 1 2014-08-01 This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
NCT02631733 ↗ Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors Active, not recruiting National Cancer Institute (NCI) Phase 1 2016-07-15 This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02785068 ↗ Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer Withdrawn Merrimack Pharmaceuticals Phase 1/Phase 2 2016-07-01 A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
NCT02826486 ↗ Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) Active, not recruiting Merck Sharp & Dohme Corp. Phase 2 2016-09-01 This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda┬«) and BL8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde┬«)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Onivyde

Condition Name

Condition Name for Onivyde
Intervention Trials
Metastatic Pancreatic Adenocarcinoma 7
Pancreatic Cancer 4
Pancreatic Adenocarcinoma 3
Colorectal Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Onivyde
Intervention Trials
Pancreatic Neoplasms 15
Adenocarcinoma 13
Carcinoma 8
Neoplasms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Onivyde

Trials by Country

Trials by Country for Onivyde
Location Trials
United States 101
Taiwan 5
Korea, Republic of 5
Spain 4
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Onivyde
Location Trials
Washington 7
Arizona 7
California 6
Florida 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Onivyde

Clinical Trial Phase

Clinical Trial Phase for Onivyde
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 2
Phase 2 12
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Onivyde
Clinical Trial Phase Trials
Recruiting 12
Active, not recruiting 9
Not yet recruiting 9
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Onivyde

Sponsor Name

Sponsor Name for Onivyde
Sponsor Trials
Ipsen 9
National Cancer Institute (NCI) 6
Merrimack Pharmaceuticals 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Onivyde
Sponsor Trials
Other 42
Industry 28
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
McKinsey
Colorcon
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.